This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In the domain of neuropharmacology and experimental therapeutics, priority is increasingly placed on novelty. As an example, in Parkinson's disease research, Neurology's 1997 indices show more than 20 entries on experimental surgery, new dopamine agonists, and catecholamine-O-methyl transferase inhibitors not yet available for patient use. In contrast, articles on drugs already available numbered only seven.
In this issue, the trend is countered as two reports examine issues related to an old drug: the antiviral/antiparkinsonian agent amantadine.1,2 Available for decades and now generic in formulation, amantadine is a tricyclic amine, well absorbed after oral administration and excreted largely unmetabolized in the urine.3 Its antiviral activity has been extensively studied and relates to inhibition of viral replication and viral uncoating.4 Its antiparkinsonian mechanism of action is more obscure, and putative effects include enhanced dopamine release, inhibition of dopamine reuptake, and antimuscarinic activities.5 Recently, however, Stoof et al.6 demonstrated amantadine's activity at glutamate receptors and suggested that antiparkinsonian effects may relate in part to …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
